Korro Bio (KRRO) Stock Price, News & Analysis

Company Overview

Korro Bio is a biotechnology company focused on developing enzyme-based catalysts to drive sustainable solutions in the petrochemical and plastics industries. Headquartered in Pasadena, California, the company leverages proprietary protein engineering and high-throughput screening technologies to design catalysts that can selectively break down or transform hydrocarbon polymers. By harnessing the specificity of enzymes, Korro Bio seeks to enable more efficient and environmentally friendly processes for polymer upcycling, recycling, and chemical manufacturing.

The core offerings of Korro Bio center on tailored biocatalysts for polyethylene deconstruction and other polymer substrates. Its platform integrates computational modeling, directed evolution, and process engineering to advance enzyme performance under industrial conditions. Early pilots have demonstrated the ability of Korro Bio’s catalysts to function at elevated temperatures and in the presence of common additives, paving the way for integration into existing chemical production and waste-recovery facilities.

Since its founding in 2018, Korro Bio has expanded its footprint beyond the United States, collaborating with partners in Europe and Asia to validate its technology at larger scales. The company has forged strategic alliances with major chemical manufacturers and recycling firms to co-develop application-specific solutions, and it maintains a state-of-the-art research facility in California to support ongoing R&D activities.

Leadership at Korro Bio comprises a multidisciplinary team of scientists and industry executives with deep expertise in enzymology, polymer chemistry, and industrial biotechnology. The executive group includes veterans from leading biotech and chemical companies, supported by an advisory board of academic researchers in protein engineering and sustainable materials. Together, they are committed to advancing Korro Bio’s mission of transforming the lifecycle of petrochemical products through innovative biocatalysis.

Key Stats

• Today's Range: $12.60 to $13.45
• 50-Day Range: $10.80 to $17.67
• 52-Week Range: $10.29 to $98.00
• Volume: 72,160 shs
• Average Volume: 107,727 shs
• Market Capitalization: $123.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $102.43
• Consensus Rating: Buy

Korro Bio Stock Analysis - MarketRank™

Korro Bio scored higher than 31% of companies evaluated by MarketBeat, and ranked 798th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Korro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Korro Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Korro Bio is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Korro Bio is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Korro Bio has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.40% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Korro Bio has recently increased by 9.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Korro Bio does not currently pay a dividend.

Dividend Growth

Korro Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.40% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Korro Bio has recently increased by 9.09%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.94

News Sentiment

Korro Bio has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Korro Bio this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for KRRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Korro Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Korro Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Korro Bio is held by insiders.

Percentage Held by Institutions

Only 13.18% of the stock of Korro Bio is held by institutions.

KRRO Stock Analysis - Frequently Asked Questions

How have KRRO shares performed this year?

Korro Bio's stock was trading at $38.07 at the beginning of the year. Since then, KRRO stock has decreased by 66.0% and is now trading at $12.9550.

How were Korro Bio's earnings last quarter?

Korro Bio, Inc. (NASDAQ:KRRO) posted its quarterly earnings results on Wednesday, May, 7th. The company reported ($2.49) earnings per share for the quarter, beating analysts' consensus estimates of ($2.60) by $0.11. The business earned $2.55 million during the quarter, compared to the consensus estimate of $0.13 million.

How do I buy shares of Korro Bio?

Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Korro Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRRO
• Previous Symbol: NASDAQ:KRRO
• CIK: 1703647
• Web: www.frequencytx.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Korro Bio: $102.43
• High Price Target: $180.00
• Low Price Target: $25.00
• Potential Upside/Downside: +701.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.58 million
• Net Margins: N/A
• Pretax Margin: -1,810.56%
• Return on Equity: -51.64%
• Return on Assets: -37.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.41
• Quick Ratio: 9.41

Sales & Book Value

• Annual Sales: $2.27 million
• Price / Sales: 52.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.12 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 9,390,000
• Free Float: 8,959,000
• Market Cap: $120.00 million
• Optionable: No Data
• Beta: 2.43